R

P

RUTKOWSKI , Piotr

Last name: RUTKOWSKI

First name: Piotr

March 5, 2024 (v1)

Publication

Metadata-only

Adjuvant pembrolizumab versus placebo in resected high risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study

Khattak, Muhammad A. Luke, Jason J. Long, Georgina V.

Abstract Background: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 study. Health-related quality of life (HRQoL) results are reported. Methods: Patients were randomly assigned 1:1 to pembrolizumab 200 mg (2 mg/kg, patients 12 to <18...

Uploaded on: March 7, 2024
August 2009 (v1)

Journal article

Metadata-only

Other targetable sarcomas.

Pires de Camargo, Veridiana van de Rijn, Matt de Alava, Enrique

Despite complex genetics, aneuploid tumors like dedifferentiated liposarcoma have specific and reproducible chromosomal changes such as amplification of HDM2 and CDK4 that represent potential targets for systemic therapy. In addition, there are cancer cell survival pathways that may not be the target of chromosomal translocations or mutations...

Uploaded on: December 3, 2022